TAIHUSNOW CO.,LTD.
838262
Guangdong Brandmax Marketing
300805
Guangdong Transtek Medical Electronics
300562
Suzhou Kingswood Education Technology
300192
Broadex Technologies
300548
CN Stock MarketDetailed Quotes
002693 Hainan Shuangcheng Pharmaceuticals
- 22.40
- +0.70+3.23%
Not Open Dec 16 15:00 CST
9.29BMarket Cap-106.67P/E (TTM)
23.00High21.56Low482.54KlotVolume21.56Open21.70Pre Close1.08BTurnover11.73%Turnover RatioLossP/E (Static)414.69MShares40.9852wk High21.41P/B9.21BFloat Cap3.6752wk Low23.87Limit Up411.38MShs Float40.98Historical High19.53Limit Down6.64%Amplitude3.41Historical Low--Dividend TTM22.41Avg Price194.91KlotAsk--Div YieldTTM100Lot Size263.94KlotBid
Hainan Shuangcheng Pharmaceuticals Key Stats
All
YOY
| (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | -30.34%126.96M | -31.74%94.89M | -47.52%42.76M | -14.13%235.93M | -7.89%182.25M | 9.62%139.01M | 11.27%81.49M | -14.22%274.75M | -21.11%197.86M | -26.98%126.81M |
| Operating revenue | -30.34%126.96M | -31.74%94.89M | -47.52%42.76M | -14.13%235.93M | -7.89%182.25M | 9.62%139.01M | 11.27%81.49M | -14.22%274.75M | -21.11%197.86M | -26.98%126.81M |
| Other operating revenue | ---- | -74.96%2.32M | ---- | -80.06%4.87M | ---- | -22.96%9.26M | ---- | 45.95%24.42M | ---- | -10.11%12.01M |
| Total operating cost | -15.28%180.5M | -20.48%119.57M | -32.46%57.36M | -15.50%278.16M | -8.88%213.05M | -2.17%150.37M | 2.62%84.92M | -12.68%329.19M | -18.39%233.83M | -20.13%153.7M |
| Operating cost | -5.60%50.85M | -8.91%36.29M | -28.21%17.08M | -15.21%74.86M | -16.78%53.86M | -4.49%39.84M | -2.61%23.79M | 8.48%88.29M | 6.61%64.72M | 2.62%41.71M |
| Operating tax surcharges | -14.72%4.35M | -18.11%2.94M | -20.05%1.5M | -13.81%6.65M | -6.66%5.1M | 0.61%3.59M | 8.20%1.88M | 9.68%7.71M | 7.92%5.46M | 14.97%3.57M |
| Operating expense | -50.29%40.07M | -54.83%27.56M | -60.75%14.6M | -18.41%102.97M | -11.43%80.6M | 3.23%61.02M | 9.05%37.2M | -33.42%126.2M | -39.81%90.99M | -43.73%59.11M |
| Administration expense | 13.83%68.62M | 16.68%42.68M | 13.45%19.16M | -6.12%76.26M | 3.80%60.29M | -5.48%36.58M | -6.85%16.89M | 3.42%81.23M | 4.55%58.08M | 8.96%38.71M |
| Financial expense | -9.08%6.58M | -14.42%4.17M | -23.38%1.97M | -15.18%9.47M | -11.24%7.24M | -10.74%4.87M | 0.04%2.57M | 12.98%11.17M | 13.95%8.16M | 19.18%5.46M |
| -Interest expense (Financial expense) | -9.39%6.68M | -15.86%4.3M | -21.28%2M | -14.36%9.58M | -12.35%7.37M | -7.39%5.11M | -0.12%2.54M | 23.87%11.19M | 23.58%8.41M | 20.21%5.51M |
| -Interest Income (Financial expense) | 2.85%-27.79K | -7.60%-20.41K | 25.00%-7.63K | 44.07%-34.48K | 55.52%-28.6K | 53.63%-18.97K | 68.32%-10.17K | -15.90%-61.66K | -19.60%-64.3K | -2.06%-40.9K |
| Research and development | 68.04%10.03M | 32.73%5.92M | 17.46%3.04M | -45.49%7.96M | -6.93%5.97M | -13.37%4.46M | 46.39%2.59M | 37.43%14.59M | -6.65%6.41M | 44.96%5.15M |
| Credit Impairment Loss | -45.44%94.17K | -122.44%-47.85K | -113.65%-20.03K | -1,330.99%-1.15M | 6.62%172.6K | 497.45%213.21K | 248.19%146.72K | 127.84%93.3K | 528.54%161.88K | -44.65%-53.64K |
| Asset Impairment Loss | -1,550.27%-348.59K | -84,257.13%-291.44K | ---- | -12.21%-3.55M | --24.04K | --346.31 | ---- | -11.48%-3.17M | ---- | ---- |
| Other net revenue | -83.02%2.21M | -92.30%780.42K | -88.31%416.07K | -168.09%-30.93M | -41.00%12.99M | -49.43%10.14M | -49.38%3.56M | 149.99%45.42M | 18.52%22.02M | 14.05%20.05M |
| Fair value change income | -80.35%27.81K | -103.62%-39.68K | -103.88%-61.14K | -70,844.66%-39.85M | -90.95%141.51K | -42.18%1.1M | --1.58M | ---56.18K | --1.56M | --1.9M |
| Invest income | -84.75%398.79K | -79.99%287.84K | 4.14%183.11K | -41.29%2.75M | 74.92%2.61M | 478.14%1.44M | 84.86%175.82K | 13.92%4.69M | -38.59%1.49M | -88.00%248.77K |
| Asset deal income | -104.59%-21.47K | -101.03%-4.89K | -101.03%-4.89K | -98.44%467.61K | -92.01%467.61K | -91.88%475.18K | --475.3K | 116.86%29.91M | -57.42%5.86M | -57.44%5.86M |
| Other revenue | -78.53%2.05M | -87.32%876.44K | -73.07%319.03K | -25.39%10.41M | -26.05%9.57M | -42.86%6.91M | -83.16%1.18M | 356.15%13.95M | 446.72%12.94M | 579.26%12.1M |
| Operating profit | -188.15%-51.33M | -1,863.11%-23.9M | -11,818.93%-14.18M | -711.78%-73.15M | -27.73%-17.81M | 82.21%-1.22M | 104.86%120.99K | 76.62%-9.01M | 18.58%-13.95M | -464.41%-6.84M |
| Add:Non operating Income | -99.61%1.73K | -100.00%1 | -99.73%1 | 141.21%564.66K | -35.02%444.64K | -34.20%444.25K | -69.73%373.29 | 83.14%234.1K | 3,139.34%684.23K | 3,149.01%675.16K |
| Less:Non operating expense | -14.86%34.57K | -24.94%27.78K | -36.14%12.03K | 265.65%378.65K | -57.90%40.61K | -47.09%37.01K | 350.26%18.83K | -94.68%103.55K | -92.42%96.45K | -94.49%69.96K |
| Total profit | -195.03%-51.36M | -2,853.48%-23.92M | -13,940.50%-14.19M | -721.62%-72.97M | -30.33%-17.41M | 87.01%-810.02K | 104.11%102.53K | 77.99%-8.88M | 27.32%-13.36M | -153.35%-6.24M |
| Less:Income tax cost | 831.88%234.62K | 1,076.15%296.12K | ---- | -157.58%-991.59K | -98.79%25.18K | -98.79%25.18K | ---955.03 | -185.56%-384.96K | --2.09M | --2.09M |
| Net profit | -195.95%-51.6M | -2,799.90%-24.22M | -13,812.77%-14.19M | -747.18%-71.98M | -12.88%-17.44M | 89.97%-835.19K | 104.15%103.48K | 79.18%-8.5M | 15.97%-15.45M | -238.10%-8.32M |
| Net profit from continuing operation | -195.95%-51.6M | -2,799.90%-24.22M | -13,812.77%-14.19M | -747.18%-71.98M | -12.88%-17.44M | 89.97%-835.19K | 104.15%103.48K | 79.18%-8.5M | 15.97%-15.45M | -238.10%-8.32M |
| Less:Minority Profit | 12.99%-13.76M | 24.43%-7.27M | -23.76%-5.45M | -21.28%-21.23M | -33.74%-15.81M | -47.86%-9.63M | -36.60%-4.4M | 14.52%-17.51M | 17.58%-11.82M | 23.04%-6.51M |
| Net profit of parent company owners | -2,234.84%-37.84M | -292.78%-16.95M | -294.04%-8.74M | -663.02%-50.74M | 55.24%-1.62M | 584.62%8.79M | 517.11%4.51M | 144.34%9.01M | 10.25%-3.62M | -130.25%-1.81M |
| Earning per share | ||||||||||
| Basic earning per share | -2,241.03%-0.0913 | -291.12%-0.0409 | -291.82%-0.0211 | -700.00%-0.12 | 61.00%-0.0039 | 575.56%0.0214 | 511.11%0.011 | 140.00%0.02 | 0.00%-0.01 | -145.00%-0.0045 |
| Diluted earning per share | -2,241.03%-0.0913 | -291.12%-0.0409 | -291.82%-0.0211 | -700.00%-0.12 | 61.00%-0.0039 | 575.56%0.0214 | 511.11%0.011 | 140.00%0.02 | 0.00%-0.01 | -145.00%-0.0045 |
| Other composite income | -131.62%-545.9 | -131.13%-3.16K | -290.61%-2.85K | 123.75%6.38K | 120.61%1.73K | 241.16%10.16K | 132.60%1.5K | -63.69%2.85K | -388.57%-8.38K | -570.55%-7.2K |
| Other composite income of parent company owners | -131.62%-545.9 | -131.13%-3.16K | -290.61%-2.85K | 123.75%6.38K | 120.61%1.73K | 241.16%10.16K | 132.60%1.5K | -63.69%2.85K | -388.57%-8.38K | -570.55%-7.2K |
| Total composite income | -195.98%-51.6M | -2,835.99%-24.22M | -13,619.93%-14.19M | -747.39%-71.97M | -12.81%-17.43M | 90.10%-825.04K | 104.20%104.98K | 79.18%-8.49M | 15.91%-15.45M | -238.60%-8.33M |
| Total composite income of parent company owners | -2,237.37%-37.84M | -292.60%-16.95M | -294.04%-8.75M | -662.77%-50.74M | 55.39%-1.62M | 583.27%8.8M | 521.22%4.51M | 144.37%9.02M | 9.98%-3.63M | -130.36%-1.82M |
| Total composite income of minority owners | 12.99%-13.76M | 24.43%-7.27M | -23.76%-5.45M | -21.28%-21.23M | -33.74%-15.81M | -47.86%-9.63M | -36.60%-4.4M | 14.52%-17.51M | 17.58%-11.82M | 23.04%-6.51M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- |
| Auditor | -- | -- | -- | Shanghui Certified Public Accountants (Special General Partnership) | -- | -- | -- | Shanghui Certified Public Accountants (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.